Hsbc Holdings PLC Lowers Holdings in Hologic, Inc. $HOLX

Key Points

• Hsbc Holdings PLC reduced its stake in Hologic, Inc. by 13.2%, selling 365,949 shares during the first quarter, and now holds $148,332,000 worth of the company's stock.
• Several hedge funds have increased their positions in Hologic, with Fuller & Thaler Asset Management boosting its stake by 57.0% during the same period.
• Analysts have mixed ratings on Hologic, with a consensus rating of "Moderate Buy" and a target price of $78.00, following recent price upgrades and downgrades.

Hsbc Holdings PLC trimmed its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,404,332 shares of the medical equipment provider's stock after selling 365,949 shares during the quarter. Hsbc Holdings PLC owned 1.08% of Hologic worth $148,332,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in HOLX. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Hologic by 57.0% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 35,575 shares of the medical equipment provider's stock worth $2,197,000 after purchasing an additional 12,910 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Hologic during the 1st quarter worth $7,005,000. Versor Investments LP lifted its stake in shares of Hologic by 37.3% during the 1st quarter. Versor Investments LP now owns 6,391 shares of the medical equipment provider's stock worth $395,000 after purchasing an additional 1,736 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Hologic by 5.2% during the 1st quarter. American Century Companies Inc. now owns 1,339,983 shares of the medical equipment provider's stock worth $82,771,000 after purchasing an additional 65,916 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Hologic by 8.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock worth $175,331,000 after purchasing an additional 213,366 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Morgan Stanley upped their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Stephens decreased their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Finally, Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Hologic presently has a consensus rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Stock Up 0.8%

Shares of HOLX stock opened at $67.82 on Wednesday. The stock's 50-day simple moving average is $65.71 and its 200-day simple moving average is $62.50. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The firm has a market capitalization of $15.08 billion, a PE ratio of 28.14, a P/E/G ratio of 2.44 and a beta of 0.49. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company's revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.